NCT01033604

Brief Summary

The application of Glyaderm for skin restoration intends to provide a more stable wound closure with enhanced pliability and function of the skin and a more favourable scar. The dermal substitute would be affordable for widespread application in full thickness skin defects and burns. Patients with burn wounds or large full thickness wounds will be evaluated before enrollment. All burn wounds that are not clearly full thickness on clinical assessment will be treated during the first 48 hours with a hydrocolloid paste and covered with a paraffin gauze dressing. This hydrocolloid paste combined with paraffin gauze will ensure maintenance of a moist wound environment for the first 48 hours prior to assessment by LDI and randomization. This is the standard treatment for all burns admitted to the Ghent Burn Centre. Wounds will be photographed on a daily basis. In order to obtain an optimal preparation for LDI, the burn wounds will be meticulously debrided during dressing changes. LDI is most reliable between 48-72 hours. Patients whose burn wounds meet the inclusion criteria, i.e. full thickness burns with LDI values \< 200 will be randomized to receive either GLYADERM and split skin graft versus split skin graft alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2007

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

December 15, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 16, 2009

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

December 5, 2014

Status Verified

December 1, 2014

Enrollment Period

4.4 years

First QC Date

December 15, 2009

Last Update Submit

December 4, 2014

Conditions

Outcome Measures

Primary Outcomes (3)

  • Comparison of healing time and percentage of autograft survival

    After one week

  • Comparison in bacterial control in full thickness defects

    On day 3,5 an 7 post application of Glyaderm

  • To assess the monitoring of dermal substitute ingrowth with Laser Doppler Imaging

    On day 3, 5 and 7 post application of Glyaderm

Secondary Outcomes (2)

  • To evaluate the functional and cosmetic outcome of skin restoration of full thickness defects treated with Glyaderm and split skin graft versus split skin graft alone

    1 month, 3, 6 and 12 months post wound closure

  • Cost-effectiveness and Health related quality of life (i.e. cost utility analysis)

    1 month, 3, 6 and 12 months post wound closure

Study Arms (2)

Glyaderm and split skin graft

EXPERIMENTAL

Full thickness defects treated with Glyaderm and split skin graft.

Procedure: Glyaderm and split skin graft

Split skin graft alone

ACTIVE COMPARATOR

Full thickness defects treated with split skin graft alone.

Procedure: Split skin graft alone.

Interventions

Full thickness defects treated with Glyaderm and split skin graft.

Glyaderm and split skin graft

Full thickness defects treated with split skin graft alone.

Split skin graft alone

Eligibility Criteria

AgeUp to 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All burn wounds with flux values measured by Laser Doppler Imaging, corresponding with an expected healing time longer than 28 days. Dark blue color on the palette of the LDI software with flux values below 200
  • All clearly full thickness burns on clinical assessment done by two plastic surgeons and thereafter treated with Flammacerium®.
  • Wounds treated with a hydrocolloid paste prior to LDI and with low flux values \< 200
  • All assessments are done during first days before final decision at day three
  • Possibility to follow the complete treatment schedule until final graft take and subsequently wound healing and finally participation on complete follow-up schedule
  • Informed consent has been obtained
  • TBSA Full Thickness Burn \< 40%

You may not qualify if:

  • All burn wounds with flux values measured by Laser Doppler Imaging, corresponding with faster healing times ( flux values \>200 )
  • TBSA \>40 %
  • Not following the complete treatment schedule or missing some evaluations during the follow-up period
  • Patient has any condition(s) that seriously compromises the patient's ability to complete this study.
  • Patient has participated in another study utilizing an investigational drug within the previous 30 days
  • Patient has one or more medical condition(s), diabetes, including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the patient an inappropriate candidate for this study
  • Patients wish to decline from the study
  • No informed consent before start of the trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Ghent

Ghent, 9000, Belgium

Location

Related Publications (1)

  • De Decker I, Hoeksema H, Verbelen J, De Coninck P, Speeckaert M, De Schepper S, Blondeel P, Pirayesh A, Monstrey S, Claes KEY. A single-stage bilayered skin reconstruction using Glyaderm(R) as an acellular dermal regeneration template results in improved scar quality: an intra-individual randomized controlled trial. Burns Trauma. 2023 May 2;11:tkad015. doi: 10.1093/burnst/tkad015. eCollection 2023.

Related Links

Study Officials

  • Stan Monstrey, MD, PhD

    University Hospital, Ghent

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2009

First Posted

December 16, 2009

Study Start

September 1, 2007

Primary Completion

February 1, 2012

Study Completion

December 1, 2012

Last Updated

December 5, 2014

Record last verified: 2014-12

Locations